Quantum Biopharma (NASDAQ:QNTM) Upgraded at Wall Street Zen

Posted by ABMN Staff on Mar 28th, 2026

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Quantum Biopharma

Quantum Biopharma Stock Up 24.5%

Shares of QNTM stock opened at $4.77 on Friday. The stock has a 50-day simple moving average of $3.96 and a 200 day simple moving average of $8.85. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $38.25. The stock has a market capitalization of $18.22 million, a P/E ratio of -0.55 and a beta of 0.32.

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.49). On average, sell-side analysts anticipate that Quantum Biopharma will post -3.27 earnings per share for the current year.

Institutional Trading of Quantum Biopharma

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Quantum Biopharma in the fourth quarter valued at $80,000. Virtu Financial LLC purchased a new position in shares of Quantum Biopharma during the fourth quarter valued at $76,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Quantum Biopharma during the second quarter valued at $63,000. 1.24% of the stock is owned by institutional investors and hedge funds.

About Quantum Biopharma

(Get Free Report)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.